Your browser doesn't support javascript.
loading
Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage.
Minami, Shohei; Kotaki, Tomohiro; Sakai, Yusuke; Okamura, Shinya; Torii, Shiho; Ono, Chikako; Motooka, Daisuke; Hamajima, Rina; Nouda, Ryotaro; Nurdin, Jeffery A; Yamasaki, Moeko; Kanai, Yuta; Ebina, Hirotaka; Maeda, Yusuke; Okamoto, Toru; Tachibana, Taro; Matsuura, Yoshiharu; Kobayashi, Takeshi.
Afiliación
  • Minami S; Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Kotaki T; Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Sakai Y; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Okamura S; Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan.
  • Torii S; The Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
  • Ono C; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Motooka D; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Hamajima R; Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
  • Nouda R; Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Nurdin JA; Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Yamasaki M; Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Kanai Y; Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Ebina H; Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Maeda Y; Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
  • Okamoto T; Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan.
  • Tachibana T; The Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
  • Matsuura Y; Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
  • Kobayashi T; Center for Advanced Modalities and DDS, Osaka University, Osaka, Japan.
Microbiol Spectr ; 12(4): e0285923, 2024 Apr 02.
Article en En | MEDLINE | ID: mdl-38415690
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes several host proteases to cleave the spike (S) protein to enter host cells. SARS-CoV-2 S protein is cleaved into S1 and S2 subunits by furin, which is closely involved in the pathogenicity of SARS-CoV-2. However, the effects of the modulated protease cleavage activity due to S protein mutations on viral replication and pathogenesis remain unclear. Herein, we serially passaged two SARS-CoV-2 strains in Vero cells and characterized the cell-adapted SARS-CoV-2 strains in vitro and in vivo. The adapted strains showed high viral growth, effective S1/S2 cleavage of the S protein, and low pathogenicity compared with the wild-type strain. Furthermore, the viral growth and S1/S2 cleavage were enhanced by the combination of the Δ68-76 and H655Y mutations using recombinant SARS-CoV-2 strains generated by the circular polymerase extension reaction. The recombinant SARS-CoV-2 strain, which contained the mutation of the adapted strain, showed increased susceptibility to the furin inhibitor, suggesting that the adapted SARS-CoV-2 strain utilized furin more effectively than the wild-type strain. Pathogenicity was attenuated by infection with effectively cleaved recombinant SARS-CoV-2 strains, suggesting that the excessive cleavage of the S proteins decreases virulence. Finally, the high-growth-adapted SARS-CoV-2 strain could be used as the seed for a low-cost inactivated vaccine; immunization with this vaccine can effectively protect the host from SARS-CoV-2 variants. Our findings provide novel insights into the growth and pathogenicity of SARS-CoV-2 in the evolution of cell-cell transmission. IMPORTANCE The efficacy of the S protein cleavage generally differs among the SARS-CoV-2 variants, resulting in distinct viral characteristics. The relationship between a mutation and the entry of SARS-CoV-2 into host cells remains unclear. In this study, we analyzed the sequence of high-growth Vero cell-adapted SARS-CoV-2 and factors determining the enhancement of the growth of the adapted virus and confirmed the characteristics of the adapted strain by analyzing the recombinant SARS-CoV-2 strain. We successfully identified mutations Δ68-76 and H655Y, which enhance viral growth and the S protein cleavage by furin. Using recombinant viruses enabled us to conduct a virus challenge experiment in vivo. The pathogenicity of SARS-CoV-2 introduced with the mutations Δ68-76, H655Y, P812L, and Q853L was attenuated in hamsters, indicating the possibility of the attenuation of excessive cleaved SARS-CoV-2. These findings provide novel insights into the infectivity and pathogenesis of SARS-CoV-2 strains, thereby significantly contributing to the field of virology.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Glicoproteína de la Espiga del Coronavirus / SARS-CoV-2 / COVID-19 Límite: Animals / Humans Idioma: En Revista: Microbiol Spectr Año: 2024 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Glicoproteína de la Espiga del Coronavirus / SARS-CoV-2 / COVID-19 Límite: Animals / Humans Idioma: En Revista: Microbiol Spectr Año: 2024 Tipo del documento: Article País de afiliación: Japón